OBJECTIVES: We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy. BACKGROUND: Diabetes mellitus is a key risk factor for chronic kidney disease (CKD). In aspirin-treated DM patients the presence of moderate/severe CKD is associated with reduced clinical efficacy of adjunctive clopidogrel therapy. Whether these findings may be attributed to differences in clopidogrel-induced effects is unknown. METHODS: This was a cross-sectional observational study in which DM patients taking maintenance aspirin and clopidogrel therapy were studied. Patients were categorized into 2 groups according to the presence or absence of moderate/severe CKD. Platelet aggregation after adenosine diphosphate (ADP) and collagen stimuli were assessed with light transmittance aggregometry and defined patients with high post-treatment platelet reactivity (HPPR). Markers of platelet activation, including glycoprotein IIb/IIIa activation and P-selectin expression, were also determined using flow cytometry. RESULTS: A total of 306 DM patients were analyzed. Patients with moderate/severe CKD (n = 84) had significantly higher ADP-induced (60 +/- 13% vs. 52 +/- 15%, p = 0.001) and collagen-induced (49 +/- 20% vs. 41 +/- 20%, p = 0.004) platelet aggregation compared with those without (n = 222). After adjustment for potential confounders, patients with moderate/severe CKD were more likely to have HPPR after ADP (adjusted odds ratio: 3.8, 95% confidence interval: 1.7 to 8.5, p = 0.001) and collagen (adjusted odds ratio: 2.4; 95% confidence interval: 1.1 to 5.4; p = 0.029) stimuli. Markers of platelet activation were significantly increased in patients with HPPR. CONCLUSIONS: In DM patients with coronary artery disease taking maintenance aspirin and clopidogrel therapy, impaired renal function is associated with reduced clopidogrel-induced antiplatelet effects and a greater prevalence of HPPR. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy. BACKGROUND:Diabetes mellitus is a key risk factor for chronic kidney disease (CKD). In aspirin-treated DMpatients the presence of moderate/severe CKD is associated with reduced clinical efficacy of adjunctive clopidogrel therapy. Whether these findings may be attributed to differences in clopidogrel-induced effects is unknown. METHODS: This was a cross-sectional observational study in which DMpatients taking maintenance aspirin and clopidogrel therapy were studied. Patients were categorized into 2 groups according to the presence or absence of moderate/severe CKD. Platelet aggregation after adenosine diphosphate (ADP) and collagen stimuli were assessed with light transmittance aggregometry and defined patients with high post-treatment platelet reactivity (HPPR). Markers of platelet activation, including glycoprotein IIb/IIIa activation and P-selectin expression, were also determined using flow cytometry. RESULTS: A total of 306 DMpatients were analyzed. Patients with moderate/severe CKD (n = 84) had significantly higher ADP-induced (60 +/- 13% vs. 52 +/- 15%, p = 0.001) and collagen-induced (49 +/- 20% vs. 41 +/- 20%, p = 0.004) platelet aggregation compared with those without (n = 222). After adjustment for potential confounders, patients with moderate/severe CKD were more likely to have HPPR after ADP (adjusted odds ratio: 3.8, 95% confidence interval: 1.7 to 8.5, p = 0.001) and collagen (adjusted odds ratio: 2.4; 95% confidence interval: 1.1 to 5.4; p = 0.029) stimuli. Markers of platelet activation were significantly increased in patients with HPPR. CONCLUSIONS: In DMpatients with coronary artery disease taking maintenance aspirin and clopidogrel therapy, impaired renal function is associated with reduced clopidogrel-induced antiplatelet effects and a greater prevalence of HPPR. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Authors: Thomas Gremmel; Karin Frühwirth; Christoph W Kopp; Alexandra Kaider; Sabine Steiner; Tamam Bakchoul; Ulrich J H Sachs; Renate Koppensteiner; Simon Panzer Journal: Clin Res Cardiol Date: 2012-01-11 Impact factor: 5.460
Authors: Melissa C Caughey; Vimal K Derebail; Nigel S Key; Alexander P Reiner; Rebecca F Gottesman; Abhijit V Kshirsagar; Gerardo Heiss Journal: Am J Hematol Date: 2019-09-10 Impact factor: 10.047
Authors: Favel L Mondesir; Todd M Brown; Paul Muntner; Raegan W Durant; April P Carson; Monika M Safford; Emily B Levitan Journal: Am Heart J Date: 2016-08-12 Impact factor: 4.749
Authors: Nishank Jain; Xilong Li; Beverley Adams-Huet; Ravi Sarode; Robert D Toto; Subhash Banerjee; S Susan Hedayati Journal: Am J Cardiol Date: 2015-12-07 Impact factor: 2.778
Authors: Antonio Tello-Montoliu; Jose Luis Ferreiro; Murali K Kodali; Masafumi Ueno; Salvatore D Tomasello; Fabiana Rollini; Davide Capodanno; Andrew Darlington; Ronakkumar Patel; Bhaloo Desai; Luis A Guzman; Theodore A Bass; Dominick J Angiolillo Journal: J Thromb Thrombolysis Date: 2013-07 Impact factor: 2.300